GALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Results of Operations and Financial Condition

GALENA BIOPHARMA, INC. (NASDAQ:GALE) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Story continues below

Results of Operations and Financial Condition.

On August 14, 2017, Galena Biopharma, Inc. (“we,” “us,” “our” and the “company”) issued a press release announcing our financial results for the three and six months ended June 30, 2017 and providing an update on recent business developments. A copy of the press release is attached to this Report as Exhibit 99.1 and is incorporated herein by reference.

The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed to be incorporated by reference in any filing by the company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.

Item 2.02

Financial Statements and Exhibits.

(d)Exhibits

ExhibitNo.

Description

99.1

Press Release of Galena Biopharma, Inc. dated August 14, 2017.


Galena Biopharma, Inc. Exhibit
EX-99.1 2 gale-20170814ex991.htm EXHIBIT 99.1 Exhibit Galena Biopharma Reports Second Quarter 2017 Financial Results San Ramon,…
To view the full exhibit click here

About GALENA BIOPHARMA, INC. (NASDAQ:GALE)

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.

An ad to help with our costs